• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 9:53:14 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARTL alert in real time by email
    SC 13G/A 1 tm216476d23_sc13ga.htm SCHEDULE 13G/A

     

     

     

    CUSIP No: 040448201

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Artelo Biosciences, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    040448201

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)
      x  Rule 13d-1(c)
      ¨  Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No: 040448201

     

    (1) NAMES OF REPORTING PERSONS
     
      CVI Investments, Inc.
     
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a)       ¨
      (b)       ¨
     
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Cayman Islands
       
    NUMBER OF   (5) SOLE VOTING POWER
           
    SHARES     0
           
    BENEFICIALLY   (6) SHARED VOTING POWER **
           
          793,672
    OWNED BY      
           
    EACH   (7) SOLE DISPOSITIVE POWER
           
    REPORTING     0
           
    PERSON WITH   (8) SHARED DISPOSITIVE POWER **
           
          793,672  
           
    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
        793,672
       
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
       
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
        4.9%
         
       
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      CO
       

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No: 040448201

     

    (1) NAMES OF REPORTING PERSONS
     
      Heights Capital Management, Inc.
       
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a)       ¨
      (b)       ¨
       
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Delaware
       
    NUMBER OF   (5) SOLE VOTING POWER
     
    SHARES     0
     
    BENEFICIALLY   (6) SHARED VOTING POWER **
     
    OWNED BY    

    793,672

         
    EACH   (7) SOLE DISPOSITIVE POWER
     
    REPORTING     0
         
     
    PERSON WITH   (8) SHARED DISPOSITIVE POWER **
     
          793,672  
           
    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
        793,672
         
     
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
       
       
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
        4.9%
         
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      CO
       

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

     

    CUSIP No: 040448201

     

    Item 1.

     

    (a)       Name of Issuer

     

    Artelo Biosciences, Inc. (the “Company”)

     

    (b)       Address of Issuer’s Principal Executive Offices

     

    888 Prospect Street, Suite 210, La Jolla, CA 92037

     

    Item 2(a).       Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b).       Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250

    San Francisco, California 94111

     

    Item 2(c).       Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)       Title of Class of Securities

     

    Common stock, $0.001 par value per share

     

    Item 2(e)       CUSIP Number

     

    040448201

     

     

     

     

    CUSIP No: 040448201

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e) ¨  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f) ¨  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g) ¨  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h) ¨  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) ¨  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) ¨  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k) ¨  Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4.       Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of Shares issuable upon the exercise of warrants to purchase Shares (the “Warrants”). The Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 4.99%.

     

    The Company’s Quarterly Report on Form 10-Q for the quarterly period ended November 30, 2020 indicates there were 15,111,587 Shares outstanding as of November 30, 2020.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

     

     

     

    CUSIP No: 040448201

     

    Item 5.       Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6.       Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.       Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8.       Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.       Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.     Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No: 040448201

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 10, 2021

     

    CVI INVESTMENTS, INC. HEIGHTS CAPITAL MANAGEMENT, INC.
           
    By: Heights Capital Management, Inc. pursuant to a Limited Power of By: /s/ Brian Sopinsky
      Attorney, a copy of which was previously filed Name:   Brian Sopinsky
        Title: Secretary
    By: /s/ Brian Sopinsky
    Name:   Brian Sopinsky  
    Title: Secretary  

     

     

     

     

    CUSIP No: 040448201

     

    EXHIBIT INDEX

     

    EXHIBIT   DESCRIPTION
    I   Limited Power of Attorney*
    II   Joint Filing Agreement*
         

    *Previously filed

     

     

     

    Get the next $ARTL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARTL

    DatePrice TargetRatingAnalyst
    7/8/2025$20.00Hold → Buy
    D. Boral Capital
    11/1/2021$4.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ARTL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models

    SOLANA BEACH, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced the publication of new peer-reviewed research from the laboratory of Dr. Steven Laviolette, Professor in the Schulich School of Medicine at the University of Western Ontario, Canada, partially funded by the Company, demonstrating that intraperitoneal administration of Artelo's proprietary FABP5 inhibitor SBFI103 produces robust anxiolytic and antidepressant-like eff

    12/3/25 8:30:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results

    SOLANA BEACH, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the three months ended September 30, 2025. "We continue to deliver on our clinical and strategic objectives, advancing three differentiated programs with strong potential to address large, underserved markets," said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. "We were very pleased with

    11/12/25 8:00:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

    SOLANA BEACH, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, announces the publication of a peer-reviewed article, "The Emerging Role of Fatty Acid Binding Protein 3 (FABP3) in Cancers", in Drug Discovery Today. The publication's lead author is Dr. George Warren, Principal Scientist at Artelo. This publication marks the third in a trilogy of reviews exploring the protumoral roles of FABP isoforms 3, 5, and 7 in cancer biology. This publication underscores growing evid

    11/4/25 8:30:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Spring Mark Edward

    3 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

    11/17/25 5:30:44 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Matsui Connie

    4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

    10/30/25 9:30:05 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Favorito Tamara A

    4 - ARTELO BIOSCIENCES, INC. (0001621221) (Issuer)

    10/30/25 9:28:31 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    SEC Filings

    View All

    SEC Form DEF 14A filed by Artelo Biosciences Inc.

    DEF 14A - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

    12/11/25 4:05:26 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Artelo Biosciences Inc.

    EFFECT - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

    12/3/25 12:15:09 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - ARTELO BIOSCIENCES, INC. (0001621221) (Filer)

    11/25/25 4:05:41 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Artelo Biosciences upgraded by D. Boral Capital with a new price target

    D. Boral Capital upgraded Artelo Biosciences from Hold to Buy and set a new price target of $20.00

    7/8/25 8:21:40 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Artelo Biosciences with a new price target

    HC Wainwright & Co. initiated coverage of Artelo Biosciences with a rating of Buy and set a new price target of $4.00

    11/1/21 6:29:39 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LADENBURG THALM/SH SH initiated coverage on Artelo Biosciences

    LADENBURG THALM/SH SH initiated coverage of Artelo Biosciences with a rating of Buy

    2/12/21 7:33:23 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    Leadership Updates

    Live Leadership Updates

    View All

    Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

    SOLANA BEACH, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced the appointment of Mark Spring, CPA, as Chief Financial Officer, effective November 1, 2025. Mr. Spring had been serving as a financial consultant to the Company since December 2024. The appointment strengthens Artelo's financial leadership as it advances its clinical pipeline and corporate growth initiatives. Mark Spring brings 30 years of experience in life sciences to his role, including f

    10/27/25 8:00:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors

    SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," comm

    5/4/21 8:00:00 AM ET
    $KTRA
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors

    LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appointment of Tamara A. Seymour, CPA, to the Company’s board of directors. “We are pleased to welcome Tamara to Artelo’s board of directors,” said Connie Matsui, Board Chair. “Tamara brings with her an impressive track record in corporate finance and capital markets, as well as extensive experience guiding biopharmaceutical and diagnostic companies from clinical stage to commercialization. We believe her advice a

    3/9/21 8:30:00 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARTL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

    SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

    2/23/22 4:36:39 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

    SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

    2/9/22 11:08:31 AM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Artelo Biosciences Inc. (Amendment)

    SC 13G/A - ARTELO BIOSCIENCES, INC. (0001621221) (Subject)

    2/4/22 3:19:12 PM ET
    $ARTL
    Biotechnology: Pharmaceutical Preparations
    Health Care